Intravenous Chelation Therapy
Intravenous Chelation Therapy works by introducing a chelating agent chiefly a chelating agent called EDTA (ethylenediaminteraceticacid) into the body to combine with toxic heavy metal elements forming an easily excretable substance. Common heavy metals that enter the body through industrial pollutants and medications are mercury, lead, aluminium and calcium. Intravenous Chelation therapy is a quick and effective heavy metal detoxification method.
Protocol for intravenous chelation therapy
Chelation therapy should be conducted on a patient only by a qualified and certified medical professional. A full physical examination should be performed and a study of the patient's full medical history, diet habits, emotional and stress levels should be examined. Blood and urine tests to determine the level of toxins in the body of the patient should be evaluated. An ECG and a chest x ray should be taken to test if the patient will be put at risk by conducting chelation therapy. The patent is given outpatient treatment and 2-3 grams of EDTA is administered intravenously 2-3 times a week for three to three and a half hour sessions. The patient must have a vitamin B and mineral supplements because chelating agents combine with essential minerals and the body could be depleted of the essential minerals that it requires.
Possible benefits of intravenous Chelation Therapy
Intravenous Chelation therapy is a quick detoxification method. It removes calcium plaque from your blood vessels and toxins from the body with a minimally invasive procedure. The FDA recognizes ETDA therapy as an effective treatment for metal poisoning.
Risks associated with intravenous chelation therapy
Treatment must be taken under the supervision of a certified and trained physician. The therapy should not be used in emergency metal poisoning cases. Patients with a history of kidney, liver and heart disease should not undergo intravenous chelation therapy. Chelation therapy is not recommended for patients with brain tumors. Pregnant and lactating women can endanger the life and health of their child by undergoing intravenous chelation therapy. Patients undergoing treatments and taking medications should not undergo intravenous chelation therapy without the consent and supervision of their physician. The side effects are headaches, nausea fatigue. A patient who becomes anemic or has unusual clotting of blood or inflammation should discontinue chelation therapy immediately.
Current research on the benefits of intravenous Chelation therapy
The American Academy of Medical Preventics now called the American College for Advancement in Medicine in Laguna Hills California and the American Board of Clinical Metal Toxicology are constantly working towards regulating protocols and ensuring the safety of ETDA therapy for detoxification. The National Institute of Health is conducting an FDA approved $ 30 million study into the effects of intravenous chelation therapy to treat coronary arterial disease.
FDA approval of Intravenous Chelation Therapy
The FDA has not evaluated the effects of intravenous chelation therapy and research is in its early stages. The treatment is regarded by the FDA as investigational. All ETDA therapy physicians must tell their patients that the therapy may not cure, treat or mitigate disease and that it does not have FDA sanction.
It is important to dedicate time to researching alternative therapies such as chelation or supplements like polysaccharides. Proper research will enable you to make an educated decision about your health.
Nature's Way - Potassium Chelate, 99 mg, 100 capsules